Exemestane (Aromasine) + Tamoxifen - Breast Neo-Adjuvant

Phase II Study Evaluating the Effectiveness of the Exemestane (Aromasin) With Tamoxifen on the Rate of Clinical Response Menopausal in Patients With Locally Advanced Breast Tumors

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00919399

Acronym

TAMARO

Enrollment

Registered

2009-06-12

Start date

2002-01-31

Completion date

2006-06-30

Last updated

2009-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Neoplasms

Keywords

breast cancer, locally advanced, Menopausal patient, aromasin, tamoxifen, efficacy

Brief summary

This is a Phase II non-randomized, open, uncontrolled and bi-centric study of hormonal induction by exemestane (Aromasin) + tamoxifen to evaluate the effectiveness of exemestane (Aromasin) with tamoxifen on the rate of clinical response menopausal in patients with tumors of locally advanced breast. Hormone therapy will be administered at a dose of 25mg/day for exemestane and 20 mg / day for 4 months for tamoxifen.

Interventions

DRUGExemestane

25mg a day during 4 months

DRUGtamoxifen

One 20 mg tablet a day started 1 week after the first Aromasine intake

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

60 Years to No maximum

Healthy volunteers

Inclusion criteria

* Breast cancer histologically proven by a 14 G or 16 G micro-biopsy to have confirmation of the diagnosis, evaluation histology prognosis grade, hormone receptors and to obtain a sample for the study of biological factors. * Menopausal patients as defined as follows: * Natural menopause \>= 1 year, or * Surgical ovariectomy. * T unilateral tumor\> 3 cm, N 1-2, M0 or M +, non-inflammatory. * Hormone receptor positive. RE positive or PR positive with histochemical technique (+ 10% of cells express the receptor) * No previous treatment of the disease by chemotherapy, hormone therapy, surgery or radiotherapy. Discontinuation of replacement therapy of menopause for at least 1 month * Age\>= 60 years * Evaluable disease * Performance Status \<= 2 * Biological function using the following criteria: * neutrophils \>= 2.10E9 / l, * Platelets\> = 100.10E9 / l, * Hemoglobin\> = 10 g / dl, * Creatinine \<= 1.5 x upper normal, * Total bilirubin \<= 1.25 x the upper normal * Transaminases (AST and ALT) \<= 1.5 x upper normal, * Alkaline phosphatase \<= 2.5 x upper normal. * Cardiac Function: electrocardiogram (ECG) normal. * Signed written consent before any procedure related to the study.

Exclusion criteria

* Men * Non Menopausal Patients * Patients with hormone receptor negative: PR- and RE - * Contra-indication to anti-estrogens (risk thrombi arteria) * Tumor \<3 cm operable * Tumor inflammatory T4d (PEV 2 or 3). * Extensive hepatic lesions (\> 1 / 3 of liver volume) * Uncontrolled cardiac disease such as angina, congestive heart failure, or arrhythmia requiring medical treatment or history of myocardial infarction within 3 months before. * History of cancer except skin cancer and basal cell cancer in situ of the cervix (a contralateral breast cancer had been no systemic treatment will be admitted). * Chronic diseases (somatic or psychiatric) in poor prognosis. * Patients who for reasons of family, social, geographical or psychological can not be followed properly. * Patients under law protection

Design outcomes

Primary

Measure	Time frame
Evaluate the objective response rate (complete response and partial response)	June 2006

Secondary

Measure	Time frame
Pharmacokinetic interaction between Exemestane and Tamoxifen	june 2006

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026